Report Highlights:
- US HIV Infection Drugs Market & Clinical Trial Insight
- Comprehensive Insight On Approved HIV Infection Drugs Price & Dosage Analysis For US Market
- HIV Infection Drugs Patent Timeline
- Dosage, Formulation, Patent, Pricing Insight by Drug Class
- 360 Page Data & Analysis On All Approved Drugs In Market
Pharmaceutical opportunities in the US related with HIV drug market is observed to be growing subsequently with time. The momentum that the US has shown towards HIV treatment is making the market a super growth attainer. Hundreds of therapies available have remained successful in opening up novel windows for harnessing immediate actions on controlling CD4+ T cells in the human body. Although the US HIV drug market hasn’t achieved a complete treatment regimen for the patients but the efficiency with which the US researchers have delivered specific drugs and therapies that could deliver better healthcare condition is magnificent when compared with other emerged markets of the world that are still adjusting to the mutative nature of the virus. It is observed for US HIV drug market that the research and development activities found in the country is believed to be providing extensive emphasis on the market acceptance and expansion at a large scale in short period of time.
The US HIV drug market will exceed billion dollars by the next few years at exponential compound annual growth rate. The prominent key drivers of the market are estimated to continue expanding in the US. One of the prominent reasons for the topline growth rate in the US is the high exchange rate dynamics and favorable dynamics for high potent antiretrovirals. For the expansion of the HIV drug market in the US, the total invoice spending is also increasing at a high compound annual growth rate. In addition to this, the net manufacturer revenue generated by HIV drug market is also expected to grow by a high percentage. As per the research conducted, the overall spending for the market growth is driven by high range of factors including increased rate of novel product uptake.
In the US, technology development is also a potential democratizing force, which is further enabling major key players in the US to enter the market. For boosting the overall market, bio-pharmaceutical companies are also increasingly including several patient centric approaches and strategies to drive certain organizational changes in the market and at last build a market capable of transducing potential healthcare benefits that could make the lives of the HIV infected patients better when compared with markets of the world.
As per the "US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report findings, it is concluded that the research and development pipelines for HIV drugs are growing at a high rate and on the brighter note, the success rate associated with the available antiretrovirals are continuing to expand at historic levels. Nevertheless, this is boosting the researchers to build an overall strong frame for clinical activity and ultimately result in novel product launches in the upcoming years. It is estimated that the future novel products developed in the US bio-pharmaceutical companies and research center will also contribute largely to the average market growth rate. The research report prepared delivers insight for the US HIV drug market, which includes the growth areas as well as the channel perspective. In the research report, the impacts of the novel drug launches are described over the traditional drugs. In addition to it, the market research report also highlights several segments to watch in the next few years for their impact on the overall growth of the market and the consumption rate.
Table of Contents
1. US HIV Drugs Market - Prevalence & Statistics
2. US HIV Drugs Market Overview
2.1 Current Market Scenario
2.2 Clinical Trials Landscape
3. US Nucleoside Reverse Transcriptase Inhibitors (NRTIs) - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
3.1 Abacavir (Ziagen)
3.2 Emtricitabine (Emtriva)
3.3 Lamivudine (Epivir)
3.4 Tenofovir Disoproxil Fumarate (Viread)
3.5 Zidovudine (Retrovir)
3.6 Stavudine (Zerit)
3.7 Didanosine (Videx/Videx EC)
4. US Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
4.1 Doravirine (Pifeltro)
4.2 Efavirenz (Sustiva)
4.3 Etravirine (Intelence)
4.4 Rilpivirine (Edurant)
4.5 Nevirapine (Viramune/Viramune XR)
5. US Protease Inhibitors (PIs) - Branded & Generic Availability, Dosage, Patent, & Price Analysis
5.1 Atazanavir (Reyataz)
5.2 Darunavir (Prezista)
5.3 Fosamprenavir (Lexiva)
5.4 Ritonavir (Norvir)
5.5 Saquinavir (Invirase)
5.6 Tipranavir (Aptivus)
5.7 Nelfinavir (Viracept)
5.8 Amprenavir (Agenerase)
5.9 Indinavir (Crixivan)
6. US Fusion Inhibitors - Branded & Generic Availability, Dosage, Patent, & Price Analysis
6.1 Enfuvirtide (Fuzeon)
7. US CCR5 Antagonists - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
7.1 Maraviroc (Selzentry)
8. US Integrase Inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
8.1 Dolutegravir (Tivicay)
8.2 Raltegravir (Isentress/Isentress HD)
9. US Attachment Inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
9.1 Ibalizumab-Uiyk (Trogarzo)
9.2 Fostemsavir (Rukobia)
10. US Pharmacokinetic Enhancers - Availability, Dosage, Patent & Price Analysis
10.1 Cobicistat (Tybost)
11. US Combinational HIV Drugs - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
11.1 Abacavir/Lamivudine (Epzicom)
11.2 Abacavir/Dolutegravir/Lamivudine (Triumeq)
11.3 Abacavir/Lamivudine/Zidovudine) Trizivir
11.4 Atazanavir/Cobicistat (Evotaz)
11.5 Bictegravir/ Emtricitabine/ Tenofovir Alafenamide (Biktarvy)
11.6 Cobicistat/Darunavir (Prezcobix)
11.7 Cobicistat/Darunavir/Emtricitabine/Tenofovir (Symtuza)
11.8 Dolutegravir/Lamivudine (Dovato)
11.9 Dolutegravir/Rilpivirine (Juluca)
11.10 Doravirine/Lamivudine/Tenofovir (Delstrigo)
11.11 Efavirenz/Emtricitabine/Tenofovir (Atripla)
11.12 Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate (Symfi/Simfi Lo)
11.13 Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide Fumarate
(Genvoya)
11.14 Cobicistat/ Elvitegravir/ Emtricitabine/ Tenofovir (Stribild)
11.15 Emtricitabine/ Rilpivirine/ Tenofovir Alafenamide (Odefsey)
11.16 Emtricitabine/Rilpivirine/Tenofovir (Complera)
11.17 Emtricitabine/Tenofovir Alafenamide (Descovy)
11.18 Emtricitabine/Tenofovir (Truvada)
11.19 Lamivudine/Tenofovir
11.20 Lamivudine/Zidovudine (Combivir)
11.21 Lopinavir/Ritonavir (Kaletra)
11.22 Cabotegravir/Rilpivirine (Cabenuva)
11.23 Emtricitabine / Nelfinavir / Tenofovir Oral Kit
11.24 Emtricitabine / Lopinavir / Ritonavir / Tenofovir Oral Kit
12. Competitive Landscape
12.1 AbbVie
12.2 AstraZeneca plc
12.3 Boehringer Ingelheim
12.4 Bristol Myers Squibb
12.5 Gilead
12.6 GlaxoSmithKline plc
12.7 Janssen Pharmaceuticals
12.8 Merck
12.9 Pfizer
12.10 Roche
12.11 Sun Pharma
12.12 ViiV Healthcare
List of Figures
Figure 1-1: US - Number of HIV Cases (Million), 2012, 2014 & 2018
Figure 1-2: US - Estimated Number of HIV Cases (Million), 2020, 2025 & 2030
Figure 1-3: US - Number of Newly Diagnosed HIV Cases & Deaths, 2018
Figure 1-4: US - Estimated Number of Newly Diagnosed HIV Cases, 2018, 2020 & 2025
Figure 1-5: US - Estimated Number of HIV Deaths, 2018, 2020 & 2025
Figure 1-6: US - HIV Incidence Rate (Per 100’000), 2014, 2018 & 2020
Figure 1-7: US - HIV Incidence Rate by Age Group (Per 100’000), 2018
Figure 1-8: US - HIV Incidence Rate by Race (Per 100’000), 2018
Figure 1-9: US - HIV Incidence Rate by Gender (Per 100’000), 2018
Figure 1-10: US - HIV Cases by Mode of Transmission (%), 2018
Figure 1-11: US - Percentage of HIV Patients by Nature of Treatment (%), 2018
Figure 2-1: Global - HIV Drug Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-2: Global - HIV Drug Market Size by Region (US$ Billion), 2020
Figure 2-3: Global - HIV Drug Market Size by Region (US$ Billion), 2020
Figure 2-4: North America - HIV Drug Market Size US v/s Others (US$ Billion), 2020
Figure 2-5: US - HIV Drug Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-6: US - Number of HIV Infection Drug Clinical Pipeline by Phase, 2021 - 2026
Figure 2-7: US - Number of HIV Infection Drugs in Clinical Pipeline by Drug Class, 2021 - 2026
Figure 2-8: US - Number of HIV Infection Drugs in Clinical Pipeline by Organization, 2021 - 2026
Figure 2-9: US - Number of HIV Infection Drugs in Clinical Pipeline by Patient Segment, 2021 - 2026
Figure 3-1: Ziagen - FDA Approval & First Generic Approval Year
Figure 3-2: Ziagen Oral Solution - Price for 240ml Supply & Price Per ml (US$), February’2021
Figure 3-3: Ziagen Tablet - Price for 60 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 3-4: Generic Abacavir Oral Solution - Price for 240ml Supply & Price Per ml (US$), February’2021
Figure 3-5: Generic Abacavir Tablet - Price for 60 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 3-6: Ziagen - Daily Treatment Cost by Dosage Form (US$)
Figure 3-7: Ziagen - Pediatric Dosage form by Weight (mg/day)
Figure 3-8: Emtriva - FDA Approval Year by Dosage Form
Figure 3-9: US - Emtriva Patent Issue & Expiration Year
Figure 3-10: Emtriva Oral Solution - Price for 170ml Supply & Price Per ml (US$), February’2021
Figure 3-11: Emtriva Tablet - Price for 30 Capsules & Price Per Unit Capsule (US$), February’2021
Figure 3-12: Emtriva - Daily Dose by Dosage Form (mg)
Figure 3-13: Emtriva: Daily Treatment Cost by Dosage Form (US$), February’2021
Figure 3-14: Epivir: FDA Approval Year by Dosage Form
Figure 3-15: Epivir: First Generic Approval Year by Dosage Form
Figure 3-16: Epivir Oral Solution - Price for 240ml Supply & Price Per ml (US$), February’2021
Figure 3-17: Epivir 150mg Tablet - Price for 60 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 3-18: Epivir 300mg Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 3-19: Generic Lamivudine Oral Solution - Price for 240ml Supply & Price Per ml (US$), February’2021
Figure 3-20: Generic Lamivudine 150mg Tablet - Price for 60 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 3-21: Generic Lamivudine 150mg Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 3-22: Generic Lamivudine 150mg Tablet - Price for 50 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 3-23: Generic Lamivudine 300mg Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 3-24: Epivir: Daily Treatment Cost by Dosage Form (US$), February’2021
Figure 3-25: Epivir - Pediatric Dosage form by Weight (mg/day)
Figure 3-26: Viread - FDA Approval Year by Dosage Form
Figure 3-27: Viread - First Generic Approval Year by Dosage Form
Figure 3-28: Viread Oral Powder - Price for 60 gm Supply & Price Per gm (US$), Februray’2021
Figure 3-29: Viread 300 mg Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), Februray’2021
Figure 3-30: Viread Tablet - Price for 30 Tablets of 150,200 & 250mg Dose & Price Per Unit Tablet (US$), Februray’2021
Figure 3-31: Generic Viread 300 mg Tablet - Average Price for 28 Tablets & Price Per Unit Tablet (US$), Februray’2021
Figure 3-32: Generic Viread 300 mg Tablet - Average Price for 30 Tablets & Price per Unit Tablet (US$), Februray’2021
Figure 3-33: Generic Viread 300 mg Tablet - Average Price for 60 Tablets & Price Per Unit Tablet (US$), Februray’2021
Figure 3-34: Generic Viread 300 mg Tablet - Average Price for 90 Tablets & Price Per Unit Tablet (US$), Februray’2021
Figure 3-35: Generic Viread 300 mg Tablet - Average Price for 180 Tablets & Price Per Unit Tablet (US$), Februray’2021
Figure 3-36: Viread Tablet - Pediatric Dose by Weight (mg/day)
Figure 3-37: Viread Oral Powder - Pediatric Dosage form by Weight (mg/day)
Figure 3-38: Viread - Daily Treatment Cost by Dosage Form (US$), February’2021
Figure 3-39: Global - Viread Annual Sales Value (US$ Million), 2017 - 2020
Figure 3-40: US - Viread Annual Sales Value (US$ Million), 2017 - 2020
Figure 3-41: Global - Viread Annual Sales Value by Region (US$ Million), 2020
Figure 3-42: Global - Viread Annual Sales Value by Region (%), 2020
Figure 3-43: Global - Viread Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 3-44: US - Viread Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 3-45: Retrovir - FDA Approval Year by Dosage Form
Figure 3-46: Retrovir - First Generic Approval Year by Dosage Form
Figure 3-47: Retrovir Intravenous Solution - Price for 100 ml Supply & Price Per ml (US$), February’2021
Figure 3-48: Retrovir Capsule - Price for 100 Capsules & Price Per Unit Capsule (US$), February’2021
Figure 3-49: Retrovir Syrup - Price for 240ml & Price Per ml (US$), February’2021
Figure 3-50: Generic Zidovudine Tablet - Price for 60 Tablets Supply & Price Per Unit Tablet (US$), February’2021
Figure 3-51: Generic Zidovudine Capsule - Price for 100 Capsules & Price Per Unit Capsule (US$), February’2021
Figure 3-52: Generic Zidovudine Syrup - Price for 240ml & Price Per ml (US$), February’2021
Figure 3-53: Retrovir Capsule - Daily, Monthly & Annual Treatment Cost (US$), February’2021
Figure 3-54: Retrovir - Oral Pediatric Dosage form by Weight (mg/Kg/day)
Figure 3-55: Zerit - FDA & First Generic Approval Year
Figure 3-56: Zerit - FDA Approval Year by Dosage Forms
Figure 3-57: Zerit - Price for 60 Capsule Supply & Price Per Unit Capsule of 15mg Dose (US$), February’2021
Figure 3-58: Zerit - Price for 60 Capsule Supply & Price Per Unit Capsule of 20mg Dose (US$), February’2021
Figure 3-59: Zerit - Price for 60 Capsule Supply & Price Per Unit Capsule of 30mg Dose (US$), February’2021
Figure 3-60: Zerit - Price for 60 Capsules & Price Per Unit Capsule (US$), February’2021
Figure 3-61: Generic Stavudine - Price for 60 Capsules of Various Dose Regimens (US$), February’2021
Figure 3-62: Zerit - Daily Adult Dose by Weight (mg)
Figure 3-63: Zerit - Minimum & Maximum Daily Treatment Cost (US$), February’2021
Figure 3-64: Zerit - Pediatric Dose by Age (mg/kg Twice Daily)
Figure 3-65: Videx - FDA Approval Year by Dosage Form
Figure 3-66: Videx Oral Powder for Reconstitution - Price for 200ml Supply & Price Per ml (US$), February’2021
Figure 3-67: Videx EC - Price for 30 Capsule Supply & Price Per Unit Capsule (US$), February’2021
Figure 3-68: Generic Videx EC - Price for 30 Capsule Supply & Price Per Unit Capsule (US$), February’2021
Figure 3-69: Videx - Daily Adult Dose by Weight (mg)
Figure 3-70: Videx - Minimum & Maximum Daily Treatment Cost (US$), February’2021
Figure 3-71: Videx - Pediatric Dose by Age (mg/m2 Daily)
Figure 3-72: Videx - Adult Dose by Weight (mg)
Figure 4-1: Pifeltro - FDA Approval Year by Type of Therapy
Figure 4-2: US - Pifeltro Patent Issue & Expiration Year
Figure 4-3: Pifeltro - Price for 30 Capsules & Price Per Unit Capsule (US$), February’2021
Figure 4-4: Pifeltro - Recommended Dose by Type of Therapy (mg/day)
Figure 4-5: Sustiva - FDA Approval Year by Dosage Form
Figure 4-6: Sustiva - First Generic Approval Year by Dosage Form
Figure 4-7: Sustiva Capsules - Price for 30 Capsule Supply & Price Per Unit Capsule of 50mg Dose (US$), February’2021
Figure 4-8: Sustiva Capsules - Price for 90 Capsule Supply & Price Per Unit Capsule of 200mg Dose (US$), February’2021
Figure 4-9: Sustiva Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 4-10: Generic Efavirenz Capsules - Price for 30 Capsule Supply & Price Per Unit Capsule of 50mg Dose (US$), February’2021
Figure 4-11: Generic Efavirenz Capsules - Price for 90 Capsule Supply & Price Per Unit Capsule of 200mg Dose (US$), February’2021
Figure 4-12: Generic Efavirenz Tablet - Price for 30 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 4-13: Sustiva - Recommended Adult Dose by Type of Therapy (mg/day), February’2021
Figure 4-14: Sustiva - Recommended Pediatric Dose by Weight (mg/day), February’2021
Figure 4-15: Intelence - FDA Approval Year by Dosage Form
Figure 4-16: US - Intelence Patent Issue & Expiration Year
Figure 4-17: Intelence - Price for 120 Tablets & Price Per Unit of 25mg & 100mg Tablet (US$), February’2021
Figure 4-18: Intelence - Price for 60 Tablets & Price Per Unit of 200mg Tablet (US$), February’2021
Figure 4-19: Intelence - Daily, Monthly & Annual treatment Cost (US$), February’2021
Figure 4-20: Intelence - Recommended Pediatric Dose by Weight (mg/day), February’2021
Figure 4-21: Edurant - Jassen’s US Patent Issue & Expiration Year
Figure 4-22: Edurant - AstraZeneca’s US Patent Issue & Expiration Year
Figure 4-23: Edurant - Price for 30 Tablet Supply & Price Per Unit Tablet of 25mg (US$), February’2021
Figure 4-24: Edurant - Daily Dose by Type of Therapy (mg), February’2021
Figure 4-25: Global - Edurant Annual Sales Value (US$ Million), 2016 - 2020
Figure 4-26: Global - Edurant Annual Sales Value (US$ Million), 2016 - 2020
Figure 4-27: Global - Edurant Annual Sales Value by Region (US$ Million), 2020
Figure 4-28: Global - Edurant Annual Sales Value by Region (%), 2020
Figure 4-29: Global - Edurant Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 4-30: US - Edurant Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 4-31: Viramune - FDA Approval Year by Dosage Form
Figure 4-32: Viramune - First Generic Approval by Dosage Form
Figure 4-33: Viramune Suspension - Price for 240ml Supply & Price Per ml (US$), February’2021
Figure 4-34: Viramune Tablet 200mg - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 4-35: Viramune XR Tablet 400mg - Price for 30 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 4-36: Generic Nevirapine Suspension - Price for 240ml Supply & Price Per ml (US$), February’2021
Figure 4-37: Generic Nevirapine Tablet 200mg - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 4-38: Generic Tablet 400mg - Price for 30 Tablets & Price Per Unit Tablet (US$), February’2021
Figure 4-39: Viramune - Oral Dose by Treatment Phase (mg/day), February’2021
Figure 4-40: Viramune - Recommended Pediatric Dose by Surface Area (mg/day), February’2021
Figure 5-1: Reyataz - FDA approval Year by Dosage Form
Figure 5-2: Reyataz Capsules - Price for 60 Capsule & Price Per Unit Capsule of 150 to 200mg (US$), February’2021
Figure 5-3: Reyataz Capsules - Price for 30 Capsule & Price Per Unit Capsule of 300mg (US$), February’2021
Figure 5-4: Reyataz Powder - Price for 30 Supply & Price Per Unit Oral Powder (US$), February’2021
Figure 5-5: Atazanavir Capsules - Price for 60 Capsule & Price Per Unit Capsule of 150 to 200mg (US$), February’2021
Figure 5-6: Atazanavir Capsules - Price for 30 Capsule & Price Per Unit Capsule of 300mg (US$), February’2021
Figure 5-7: Reyataz - Dose by Treatment Therapy (mg/day), February’2021
Figure 5-8: Reyataz - Recommended Pediatric Dose by Weight (mg/day), February’2021
Figure 5-9: Prezista - FDA approval Year by Dosage Form
Figure 5-10: US - Prezista Patent Issue & Expiration Year by Assignee
Figure 5-11: Prezista Suspension - Price for a Supply of 200ml & Price Per ml (US$), February’2021
Figure 5-12: Prezista Tablet - Price per unit of Various Doses (US$), February’2021
Figure 5-13: Reyataz - Dose by Type of HIV Patient (mg/day), February’2021
Figure 5-14: Reyataz - Daily Treatment Cost for Treatment Naïve Patients by Dosage Form (mg/day), February’2021
Figure 5-15: Lexiva - FDA approval Year by Dosage Form
Figure 5-16: Lexivia Suspension - Price for a Supply of 225ml & Price Per ml (US$), February’2021
Figure 5-17: Lexivia Tablet - Price for 60 Tablet Supply & Price Per Unit (US$), February’2021
Figure 5-18: Generic Fosamprenavir Tablet - Price for 60 Tablet Supply & Price Per Unit (US$), February’2021
Figure 5-19: Lexivia - Dose by Treatment Therapy (mg/day), February’2021
Figure 5-20: Lexivia - Recommended Pediatric Dose by Weight (mg/Kg Twice daily), February’2021
Figure 5-21: Norvir - FDA approval Year by Dosage Form
Figure 5-22: US - Norvir Patent Issue & Expiration Year
Figure 5-23: Norvir Powder - Price for a Supply of 30 Powders & Price Per Unit (US$), February’2021
Figure 5-24: Norvir Tablet - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 5-25: Norvir Solution - Price for 240ml Supply & Price Per ml (US$), February’2021
Figure 5-26: Generic Ritonavir Tablet - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 5-27: Norvir - Daily Treatment Cost by Dosage Form (US$), February’2021
Figure 5-28: Norvir - FDA approval Year by Dosage Form
Figure 5-29: Invirase Tablet - Price for 120 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 5-30: Invirase Tablet - Daily Dose During Initial 7 days v/s After 7 Days (mg/day), February’2021
Figure 5-31: Invirase Tablet - Daily Treatment Cost During Initial Week v/s After Initial Week (mg/day), February’2021
Figure 5-32: Aptivus - FDA approval Year by Dosage Form
Figure 5-33: Aptivus - Price for 120 Capsule Supply & Price Per Unit Capsule (US$), February’2021
Figure 5-34: Aptivus Solution - Price for 95ml Supply & Price Per ml (US$), February’2021
Figure 5-35: Aptivus - Daily Treatment Cost by Dosage Form (US$), February’2021
Figure 5-36: Viracept - FDA approval Year by Dosage Form
Figure 5-37: Viracept - Price for a Supply of 300 Tablets & Price Per Unit Tablet of 250mg (US$), February’2021
Figure 5-38: Viracept - Price for a Supply of 120 Tablets & Price Per Unit Tablet of 625mg (US$), February’2021
Figure 5-39: Viracept - Daily Minimum & Maximum Dose (mg), February’2021
Figure 5-40: Viracept Tablet - Daily Minimum & Maximum Treatment Cost (US$), February’2021
Figure 5-41: Agenerase - FDA Approval & Patent Expiration Year
Figure 5-42: Agenerase - Price for 480 Capsule Supply & Price Per Unit Capsule of 50 mg (US$), February’2021
Figure 5-43: Agenerase - Recommended Dose by Type of Therapy (mg), February’2021
Figure 5-44: Crixivan - FDA approval Year by Dosage Form
Figure 5-45: Crixivan - Patent Issue & Expiration Year
Figure 5-46: Crixivan - Price for a Supply of 360 Capsules & Price Per Unit Capsules of 200mg (US$), February’2021
Figure 5-47: Crixivan - Price for a Supply of 180 Capsules & Price Per Unit Capsules of 400mg (US$), February’2021
Figure 5-48: Crixivan - Recommended Dose by Therapy Type (mg/day), February’2021
Figure 5-49: Crixivan - Average cost of Single Dose & Daily Treatment Cost (US$), February’2021
Figure 6-1: US - Fuzeon Patent Issue & Expiration Year
Figure 6-2: Fuzeon - Price for a Supply of 60 Powders & Price Per Unit of 90mg Powder (US$), February’2021
Figure 6-3: Fuzeon - Cost of Daily, Monthly & Annual Treatment (US$), February’2021
Figure 7-1: Selzentry - FDA approval Year by Dosage Form
Figure 7-2: US - Selzentry Patent Issue & Expiration Year
Figure 7-3: Selzentry Oral Liquid - Price for a Supply of 230 ml & Price Per ml of 90mg (US$), February’2021
Figure 7-4: Selzentry Tablets - Price for a Supply of 120 Tablets & Price Per Unit of 25mg & 75mg Tablet (US$), February’2021
Figure 7-5: Selzentry Tablets - Price for a Supply of 120 Tablets & Price Per Unit of 150mg & 300mg Tablet (US$), February’2021
Figure 7-6: Selzentry - Daily Dose by Combination Agent (mg), February’2021
Figure 7-7: Selzentry - Daily Pediatric Dose in Combination in Combination with Potent CYP450 3A Inhibitors by Weight (mg), February’2021
Figure 7-8: Global - Selzentry Annual Sales Value (US$/GBP Million), 2017 - 2020
Figure 7-9: US - Selzentry Annual Sales Value (US$/GBP Million), 2017 - 2020
Figure 7-10: Selzentry - Annual Sales Value by Region (US$/GBP Million), 2020
Figure 7-11: Selzentry - Annual Sales Value by Region (%), 2020
Figure 7-12: Global - Selzentry Quarterly Sales Value (US$/GBP Million), 2020
Figure 7-13: US - Selzentry Quarterly Sales Value (US$/GBP Million), 2020
Figure 8-1: Tivicay - FDA approval Year by Dosage Form
Figure 8-2: US - Tivicay Patent Issue & Expiration Year
Figure 8-3: Tivicay - Price for a Supply of 30 Tablets & Price Per Unit Tablet of Various Doses (US$), February’2021
Figure 8-4: Tivicay - Minimum & Maximum Daily Dose (mg), February’2021
Figure 8-5: Tivicay - Minimum & Maximum Daily Treatment Cost (US$), February’2021
Figure 8-6: Tivicay - Pediatric Dose by Weight of Patient (mg), February’2021
Figure 8-7: Global - Tivicay Annual Sales Value (US$/GBP Million), 2017 - 2020
Figure 8-8: Global - Tivicay Annual Sales Value by Region (US$/GBP Million), 2020
Figure 8-9: Global - Tivicay Annual Sales Value by Region (%), 2020
Figure 8-10: Global - Tivicay Quarterly Sales Value (US$/GBP Million), 2020
Figure 8-11: US - Tivicay Quarterly Sales Value (US$/GBP Million), 2020
Figure 8-12: Isentress - FDA approval Year by Dosage Form
Figure 8-13: Isentress - Istituto Di Ricerche Di Biologia Molecolare’s Patent Issue & Expiration Year
Figure 8-14: Isentress - Merck’s Patent Issue & Expiration Year
Figure 8-15: Isentress - Price for 60 Granule Supply & Price Per Unit of 100mg Granules (US$), February’2021
Figure 8-16: Isentress - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 8-17: Isentress - Price for a Supply of 60 Chewable Tablets & Price Per Unit Tablet of Various Doses (US$), February’2021
Figure 8-18: Isentress HD - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 8-19: Isentress - Recommended Dose by Patient Type (mg/day), February’2021
Figure 8-20: Global - Isentress/Isentress HD Annual Sales Value (US$ Million), 2017 - 2020
Figure 8-21: Global - Isentress Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 9-1: Trogarzo - FDA Approval & Patent Expiration Year
Figure 9-2: Trogarzo - Price for 2.66ml Supply & Price Per ml of Intravenous Solution (US$), February’2021
Figure 9-3: Trogarzo - Loading Dose v/s Maintenance Dose (mg/2 Weeks), February’2021
Figure 9-4: Trogarzo - Cost of Loading Dose v/s Maintenance Dose (US$), February’2021
Figure 9-5: Global - Trogarzo Annual Sales (US$ Million), 2018 & 2019
Figure 9-6: US - Rukobia Patent Issue & Expiration Year
Figure 9-7: Rukobia - Price for 60 Tablets Supply & Price Per Unit of 600mg Tablet (US$), Februray’2021
Figure 9-8: Rukobia - Cost of Daily & Monthly Treatment (US$), Februray’2021
Figure 10-1: US - Tybost Patent Issue & Expiration Year
Figure 10-2: Tybost - Price for 30 Tablets Supply & Price Per Unit of 150mg (US$), February’2021
Figure 11-1: Epzicom - FDA Approval & First Generic Approval
Figure 11-2: Epzicom - Price for 30 Tablets Supply & Price per unit Tablet (US$), February’2021
Figure 11-3: Generic Abacavir/Lamivudine - Price for 30 Tablets Supply & Price Per Unit of 150mg (US$), February’2021
Figure 11-4: Epzicom - Daily, Monthly & Annual Treatment Cost (US$), February’2021
Figure 11-5: Global - Epzicom/Kivexa Annual Sales Value (US$/GBP Million), 2017 - 2020
Figure 11-6: US - Epzicom/Kivexa Annual Sales Value (US$/GBP Million), 2017 - 2020
Figure 11-7: Epzicom/Kivexa - Annual Sales Value by Region (US$/GBP Million), 2020
Figure 11-8: Epzicom/Kivexa - Annual Sales Value by Region (%), 2020
Figure 11-9: Global - Epzicom/Kivexa Quarterly Sales Value (US$ Million), 2020
Figure 11-10: US - Triumeq Patent Issue & Expiration Year
Figure 11-11: Epzicom - Price for 30 Tablets Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-12: Global - Triumeq Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-13: US - Triumeq Annual Sales Value by Region (US$/GBP Million), 2020
Figure 11-14: Triumeq - Annual Sales Value by Region (%), 2020
Figure 11-15: Global - Triumeq Quarterly Sales Value (US$/GBP Million), 2020
Figure 11-16: US - Triumeq Quarterly Sales Value (US$/GBP Million), 2020
Figure 11-17: Trizivir - FDA Approval & First Generic Approval
Figure 11-18: Trizivir - Price for 60 Tablets Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-19: Generic Trizivir - Price for 60 Tablets Supply & Price Per Unit of 150mg (US$), February’2021
Figure 11-20: Trizivir - Daily, Monthly & Annual Treatment Cost (US$), February’2021
Figure 11-21: US - Evotaz Patent Issue & Expiration Year
Figure 11-22: Evotaz - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-23: Biktarvy - Gilead’s US Patent Issue & Expiration Year
Figure 11-24: Biktarvy - Emory’s US Patent Issue & Expiration Year
Figure 11-25: Biktarvy - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-26: Global - Biktarvy Annual Sales Value (US$ Billion), 2018 - 2020
Figure 11-27: Global - Biktarvy Annual Sales Value by Region (US$ Million), 2020
Figure 11-28: Biktarvy - Annual Sales Value by Region (%), 2020
Figure 11-29: Global - Biktarvy Quarterly Sales Value (US$ Million), 2019 - 2020
Figure 11-30: US - Biktarvy Quarterly Sales Value (US$ Million), 2019 - 2020
Figure 11-31: Prezcobix - Gilead’s US Patent Issue & Expiration Year
Figure 11-32: Prezcobix - Tibotic’s US Patent Issue & Expiration Year
Figure 11-33: Prezcobix - Janssen’s US Patent Issue & Expiration Year
Figure 11-34: Prezcobix - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-35: Symtuza - Gilead’s US Patent Issue & Expiration Year
Figure 11-36: Symtuza - Emory’s US Patent Issue & Expiration Year
Figure 11-37: Symtuza - Tibotic’s US Patent Issue & Expiration Year
Figure 11-38: Symtuza - Janssen’s US Patent Issue & Expiration Year
Figure 11-39: Symtuza - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-40: Dovato - GSK’s US Patent Issue & Expiration Year
Figure 11-41: Dovato - VIIV’s US Patent Issue & Expiration Year
Figure 11-42: Dovato - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-43: Global - Dovato Annual Sales Value by Region (US$/GBP Million), 2019 &2020
Figure 11-44: US - Dovato Annual Sales Value by Region (US$/GBP Million), 2019 & 2020
Figure 11-45: Dovato - Annual Sales Value by Region (US$/GBP Million), 2020
Figure 11-46: Dovato - Annual Sales Value by Region (%), 2020
Figure 11-47: Global - Dovato Quarterly Sales Value (US$/GBP Million), 2020
Figure 11-48: US - Dovato Quarterly Sales Value (US$/GBP Million), 2020
Figure 11-49: US - Juluca Number of Patent Issued by Assignee Name
Figure 11-50: US - Juluca Patent Expiration Year by Assignee
Figure 11-51: Juluca - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-52: Global - Juluca Annual Sales Value (US$/GBP Million), 2017 - 2020
Figure 11-53: US - Juluca Annual Sales Value (US$/GBP Million), 2017 - 2020
Figure 11-54: Juluca - Annual Sales Value by Region (US$/GBP Million), 2020
Figure 11-55: Juluca - Annual Sales Value by Region (%), 2020
Figure 11-56: Global - Juluca Quarterly Sales Value (US$/GBP Million), 2020
Figure 11-57: US - Juluca Quarterly Sales Value (US$/GBP Million), 2020
Figure 11-58: US - Delstrigo Patent Issue & Expiration Year
Figure 11-59: Delstrigo - Price for 30 tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-60: Delstrigo - Daily, Monthly & Annual Treatment Cost (US$), February’2021
Figure 11-61: Atripla - FDA approval & Generic Approval Year
Figure 11-62: Alripla - Gilead’s US Patent Issue & Expiration Year
Figure 11-63: Atripla - Emory’s US Patent Issue & Expiration Year
Figure 11-64: Atripla - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-65: Generic Atripla - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-66: Global - Atripla Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-67: US - Atripla Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-68: Atripla - Annual Sales Value by Region (US$ Million), 2020
Figure 11-69: Atripla - Annual Sales Value by Region (%), 2020
Figure 11-70: Global - Atripla Quarterly Sales Value (US$ Million), 2020
Figure 11-71: US - Atripla Quarterly Sales Value (US$ Million), 2020
Figure 11-72: Simfi/Simfi Lo - FDA approval Year
Figure 11-73: Simfi/Simfi Lo - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-74: Genvoya - Number of US Patent Issued by Assignee Name
Figure 11-75: Genvoya - US Patent Expiration Year by Assignee
Figure 11-76: Genvoya - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-77: Global - Genvoya Annual Sales Value (US$ Billion), 2017 - 2020
Figure 11-78: US - Genvoya Annual Sales Value (US$ Billion), 2017 - 2020
Figure 11-79: Genvoya - Annual Sales Value by Region (US$ Million), 2020
Figure 11-80: Genvoya - Annual Sales Value by Region (%), 2020
Figure 11-81: Global - Genvoya Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-82: US - Genvoya Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-83: Stribild - Number of US Patent Issued by Assignee Name
Figure 11-84: US - Stribild Patent Expiration Year by Assignee
Figure 11-85: Stribild - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-86: Global - Stribild Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-87: US - Stribild Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-88: Stribild - Annual Sales Value by Region (US$ Million), 2020
Figure 11-89: Stribild - Annual Sales Value by Region (%), 2020
Figure 11-90: Global - Stribild Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-91: US - Stribild Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-92: Odefsey - Number of US Patent Issued by Assignee Name
Figure 11-93: US - Odefsey Patent Expiration Year by Assignee
Figure 11-94: Odefsey - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-95: Global - Odefsey Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-96: Global - Odefsey Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-97: Odefsey - Annual Sales Value by Region (US$ Million), 2020
Figure 11-98: Odefsey - Annual Sales Value by Region (%), 2020
Figure 11-99: Global - Odefsey Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-100: US - Odefsey Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-101: Complera - Number of US Patent Issued by Assignee Name
Figure 11-102: Complera - US Patent Expiration Year by Assignee
Figure 11-103: Complera - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-104: Complera - Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-105: Complera - Annual Sales Value by Region (US$ Million), 2020
Figure 11-106: Complera - Annual Sales Value by Region (%), 2020
Figure 11-107: Global - Complera Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-108: US - Complera Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-109: Descovy - Number of US Patents Issued by Assignee Name
Figure 11-110: Descovy - US Patent Expiration Year by Assignee
Figure 11-111: Descovy - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-112: Descovy - Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-113: Descovy - Annual Sales Value by Region (US$ Million), 2020
Figure 11-114: Descovy - Annual Sales Value by Region (%), 2020
Figure 11-115: Global - Descovy Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-116: US - Descovy Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-117: Truvada - Number of US Patent Issued by Assignee Name
Figure 11-118: US - Descovy Patent Expiration Year by Assignee
Figure 11-119: Truvada: Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-120: Truvada - Annual Sales Value (US$ Million), 2017 - 2020
Figure 11-121: Truvada - Annual Sales Value by Region (US$ Million), 2020
Figure 11-122: Truvada - Annual Sales Value by Region (%), 2020
Figure 11-123: Global - Truvada Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-124: US - Truvada Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 11-125: Cimduo - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-126: Temixys - Price for 30 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-127: Combivir - FDA & First Generic Approval Year
Figure 11-128: Combivir - Price for 60 Tablet Supply & Price Per Unit Tablet (US$), February’2021
Figure 11-129: Generic Combivir - Price for various Supplies of Oral Tablet (US$), February’2021
Figure 11-130: Kaletra - FDA Approval Year by Dosage Form
Figure 11-131: Kaletra Oral Solution - Branded v/s Generic Price for 160 ml Supply & Price Per ml of (US$), February’2021
Figure 11-132: Kaletra Oral Tablet - Price for 60 Tablet & Price per unit Tablets of 100mg-25mg Dose (US$), February’2021
Figure 11-133: Kaletra Oral Tablet - Price for 12 Tablet & 120 Tablet Supply of 200mg-50mg Dose (US$), February’2021
Figure 11-134: Cabenuva - Price for Various Supplies of Cabenuva Suspension Kit (US$), February’2021
Figure 11-135: Cabenuva - Recommended Initial & Subsequent Dose (mg/Month),
Figure 11-136: Emtricitabine / Nelfinavir / Tenofovir Oral Kit - Price Per Unit by Product (US$), February’2021
Figure 11-137: Emtricitabine / Nelfinavir / Tenofovir Oral Kit - Price Per Unit by Product (US$), February’2021"
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- AstraZeneca plc
- Boehringer Ingelheim
- Bristol Myers Squibb
- Gilead
- GlaxoSmithKline plc
- Janssen Pharmaceuticals
- Merck
- Pfizer
- Roche
- Sun Pharma
- ViiV Healthcare
